Dr. Zvi Margaliot, MD Plastic Surgery - Surgery of the Hand Medicare: Not Enrolled in Medicare Practice Location: 15390 Nw Cornell Rd Ste 225, Beaverton, OR 97006 Phone: 503-601-2910 Fax: 503-601-2910 |
News Archive
Great Lakes NeuroTechnologies Secures Over $4.5 Million in Funding to Fuel New Product Development for Parkinson's Disease and Neuroscience Education April 24, 2012: Valley View, OH - Great Lakes NeuroTechnologies announced today they have secured over $4.5 million is funding for new product development. The funding includes three new projects sponsored by the National Institutes of Health's SBIR program. Each project is focused on developing and testing innovative neurotechnology. Two projects focus on the monitoring and treatment of Parkinson's disease while another will develop a wireless physiological monitor and web-based teaching system for high school neuroscience courses.
EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that the US Food and Drug Administration (FDA) has approved its orphan drug ERWINAZE (asparaginase Erwinia chrysanthemi) for the treatment of acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to E. coli-derived asparaginase.
Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.
In the largest study of its kind, physicians from the Department of Surgery at the University of Maryland School of Medicine and the R Adams Cowley Shock Trauma Center at the University of Maryland Medical Center have determined that outcomes for traumatic injury in patients with organ transplants are not worse than for non-transplanted patients, despite common presumptions among physicians.
› Verified 1 days ago